Lorenza Scarpa1, Sabine Buxbaum1, Dorota Kendler1, Katharina Fink1,2, Jasmin Bektic3, Leonhard Gruber4, Clemens Decristoforo1, Christian Uprimny1, Peter Lukas2, Wolfgang Horninger3, Irene Virgolini5. 1. Department of Nuclear Medicine, Medical University Innsbruck, Anichstraße 35, A-6020, Innsbruck, Austria. 2. Department of Radiotherapy / Radiation Oncology, Medical University of Innsbruck, Innsbruck, Austria. 3. Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. 4. Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria. 5. Department of Nuclear Medicine, Medical University Innsbruck, Anichstraße 35, A-6020, Innsbruck, Austria. irene.virgolini@i-med.ac.at.
Abstract
INTRODUCTION: A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Ten consecutive mCRPC patients were selected for 177Lu-PSMA617 therapy on the basis of PSMA-targeted 68Ga-PSMA-HBED-CC PET/CT diagnosis showing extensive and progressive tumour load. Following dosimetry along with the first therapy cycle restaging (68Ga-PSMA-HBED-CC and 18F-NaF PET/CT) was performed after 2 and 3 therapy cycles (each 6.1 ± 0.3 GBq, range 5.4-6.5 GBq) given intravenously over 30 minutes, 9 ± 1 weeks apart. PET/CT scans were compared to 177Lu-PSMA617 24-hour whole-body scans and contrast-enhanced dual-phase CT. Detailed comparison of SUVmax values and absorbed tumour doses was performed. RESULTS: 177Lu-PSMA617 dosimetry indicated high tumour doses for skeletal (3.4 ± 1.9 Gy/GBq; range 1.1-7.2 Gy/GBq), lymph node (2.6 ± 0.4 Gy/GBq; range 2.3-2.9 Gy/GBq) as well as liver (2.4 ± 0.8 Gy/GBq; range 1.7-3.3 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 18 ± 0.3 GBq. Three patients showed partial remission, three mixed response, one stable and three progressive disease. Decreased 177Lu-PSMA617 and 68Ga-PSMA-HBED-CC uptake (mean SUVmax values 20.2 before and 15.0 after 2 cycles and 11.5 after 3 cycles, p < 0.05) was found in 41/54 skeletal lesions, 12/13 lymph node metastases, 3/5 visceral metastases and 4/4 primary PC lesions. CONCLUSION: Due to substantial individual variance, dosimetry is mandatory for a patient-specific approach following 177Lu-PSMA617 therapy. Higher activities and/or shorter treatment intervals should be applied in a larger prospective study.
INTRODUCTION: A targeted theragnostic approach based on increased expression of prostate-specific membrane antigen (PSMA) on PC cells is an attractive treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Ten consecutive mCRPC patients were selected for 177Lu-PSMA617 therapy on the basis of PSMA-targeted 68Ga-PSMA-HBED-CC PET/CT diagnosis showing extensive and progressive tumour load. Following dosimetry along with the first therapy cycle restaging (68Ga-PSMA-HBED-CC and 18F-NaF PET/CT) was performed after 2 and 3 therapy cycles (each 6.1 ± 0.3 GBq, range 5.4-6.5 GBq) given intravenously over 30 minutes, 9 ± 1 weeks apart. PET/CT scans were compared to 177Lu-PSMA617 24-hour whole-body scans and contrast-enhanced dual-phase CT. Detailed comparison of SUVmax values and absorbed tumour doses was performed. RESULTS: 177Lu-PSMA617 dosimetry indicated high tumour doses for skeletal (3.4 ± 1.9 Gy/GBq; range 1.1-7.2 Gy/GBq), lymph node (2.6 ± 0.4 Gy/GBq; range 2.3-2.9 Gy/GBq) as well as liver (2.4 ± 0.8 Gy/GBq; range 1.7-3.3 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 18 ± 0.3 GBq. Three patients showed partial remission, three mixed response, one stable and three progressive disease. Decreased 177Lu-PSMA617 and 68Ga-PSMA-HBED-CC uptake (mean SUVmax values 20.2 before and 15.0 after 2 cycles and 11.5 after 3 cycles, p < 0.05) was found in 41/54 skeletal lesions, 12/13 lymph node metastases, 3/5 visceral metastases and 4/4 primary PC lesions. CONCLUSION: Due to substantial individual variance, dosimetry is mandatory for a patient-specific approach following 177Lu-PSMA617 therapy. Higher activities and/or shorter treatment intervals should be applied in a larger prospective study.
Entities:
Keywords:
18F-NaF-PET; 68Ga/177 Lu-PSMA-targeted theragnostic concept; Dosimetry; Prostate cancer
Authors: Kambiz Rahbar; Matthias Schmidt; Alexander Heinzel; Elisabeth Eppard; Axel Bode; Anna Yordanova; Michael Claesener; Hojjat Ahmadzadehfar Journal: J Nucl Med Date: 2016-04-07 Impact factor: 10.057
Authors: Milos Petrik; Peter A Knetsch; Roger Knopp; Giovanni Imperato; Meltem Ocak; Elisabeth von Guggenberg; Roland Haubner; Roland Silbernagl; Clemens Decristoforo Journal: Nucl Med Commun Date: 2011-10 Impact factor: 1.690
Authors: Shankar Vallabhajosula; Anastasia Nikolopoulou; John W Babich; Joseph R Osborne; Scott T Tagawa; Irina Lipai; Lilja Solnes; Kevin P Maresca; Thomas Armor; John L Joyal; Robert Crummet; James B Stubbs; Stanley J Goldsmith Journal: J Nucl Med Date: 2014-10-23 Impact factor: 10.057
Authors: Ana P Kiess; Il Minn; Ganesan Vaidyanathan; Robert F Hobbs; Anders Josefsson; Colette Shen; Mary Brummet; Ying Chen; Jaeyeon Choi; Eftychia Koumarianou; Kwamena Baidoo; Martin W Brechbiel; Ronnie C Mease; George Sgouros; Michael R Zalutsky; Martin G Pomper Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057
Authors: Il Minn; Ying Chen; Ana P Kiess; Robert Hobbs; George Sgouros; Ronnie C Mease; Mrudula Pullambhatla; Colette J Shen; Catherine A Foss; Martin G Pomper Journal: J Nucl Med Date: 2015-07-16 Impact factor: 10.057
Authors: Shankar Vallabhajosula; Stanley J Goldsmith; Klaus A Hamacher; Lale Kostakoglu; Shota Konishi; Mathew I Milowski; David M Nanus; Neil H Bander Journal: J Nucl Med Date: 2005-05 Impact factor: 10.057
Authors: Shozo Okamoto; Anne Thieme; Jakob Allmann; Calogero D'Alessandria; Tobias Maurer; Margitta Retz; Robert Tauber; Matthias M Heck; Hans-Juergen Wester; Nagara Tamaki; Wolfgang P Fendler; Ken Herrmann; Christian H Pfob; Klemens Scheidhauer; Markus Schwaiger; Sibylle Ziegler; Matthias Eiber Journal: J Nucl Med Date: 2016-09-22 Impact factor: 10.057
Authors: Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-26 Impact factor: 9.236
Authors: Florian Sterzing; Clemens Kratochwil; Hannah Fiedler; Sonja Katayama; Gregor Habl; Klaus Kopka; Ali Afshar-Oromieh; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-25 Impact factor: 9.236
Authors: Ganesan Vaidyanathan; Choong Mo Kang; Darryl McDougald; Il Minn; Mary Brummet; Martin G Pomper; Michael R Zalutsky Journal: Nucl Med Biol Date: 2018-05-05 Impact factor: 2.408
Authors: Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-22 Impact factor: 9.236
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe Journal: Eur Urol Date: 2021-04-08 Impact factor: 20.096
Authors: Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom Journal: Cancers (Basel) Date: 2021-04-22 Impact factor: 6.639
Authors: Amanda Kristiansson; Anders Örbom; Jonas Ahlstedt; Helena Karlsson; Wahed Zedan; Magnus Gram; Bo Åkerström; Sven-Erik Strand; Mohamed Altai; Joanna Strand; Oskar Vilhelmsson Timmermand Journal: Biomolecules Date: 2021-02-10